pdufa
.bio
Calendar
Decisions
Research
Home
›
Decisions
› AZN 2026-04-27
AZN
FDA decision
— Apr 27, 2026
✓ APPROVED
AstraZeneca PLC — SAPHNELO (anifrolumab-fnia) · Systemic lupus erythematosus (SLE).
Run-up into the decision (T-120 → T+5)
PDUFA 4/27/26
$209.48
$162.3
11/10/25
Daily close, T-120 (11/10/25) through T+5. Run-up high $209.48 on 2/18/26, low $162.3 on 11/13/25 (T-120 to T-1). FDA decision 4/27/26. Historical price action, not a forecast.
Key facts
FDA decision date
2026-04-27
Outcome
Approved
Drug / candidate
SAPHNELO (anifrolumab-fnia)
Company
AstraZeneca PLC
120-day run-up (T-120→T-1)
+15.1%
Not affiliated with or endorsed by the FDA.
Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio